Edmond DE Rothschild Holding S.A. Lowers Position in Edwards Lifesciences Co. (NYSE:EW)

Edmond DE Rothschild Holding S.A. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 645,587 shares of the medical research company’s stock after selling 13,747 shares during the period. Edwards Lifesciences accounts for 0.8% of Edmond DE Rothschild Holding S.A.’s portfolio, making the stock its 28th largest position. Edmond DE Rothschild Holding S.A.’s holdings in Edwards Lifesciences were worth $47,793,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Abacus Planning Group Inc. boosted its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after purchasing an additional 140 shares during the period. Bowman & Co S.C. increased its stake in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 148 shares during the period. Moors & Cabot Inc. raised its holdings in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after buying an additional 152 shares during the last quarter. Pegasus Asset Management Inc. boosted its position in shares of Edwards Lifesciences by 0.4% during the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after buying an additional 159 shares during the period. Finally, Mount Yale Investment Advisors LLC grew its holdings in Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after buying an additional 162 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $79.95.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

EW stock opened at $70.90 on Monday. The firm has a 50-day moving average of $71.49 and a two-hundred day moving average of $70.53. The firm has a market capitalization of $41.68 billion, a PE ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.73.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.